Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

1,040

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

November 8, 2023

Study Completion Date

November 8, 2023

Conditions
Atrial FibrillationCoronary Artery DiseaseStable AnginaStable Chronic Angina
Interventions
DRUG

Edoxaban Monotherapy

Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.

DRUG

Edoxaban plus Single Antiplatelet Agent

Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.

Trial Locations (18)

Unknown

Hallym University Medical Center, Anyang

Soon Chun Hyang University Hospital Bucheon, Bucheon-si

Keimyung University Dongsan Medical Center, Daegu

Dongguk University Ilsan Hospital, Ilsan

Dong-A University Hospital, Pusan

Inje University Haeundae Paik Hospital, Pusan

Seoul National University Bundang Hospital, Seongnam

Asan Medical Center, Seoul

Kangdong KyungHee University hospital, Seoul

Konkuk University Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Seoul

The Catholic Univ.of Korea Eunpyeong St.Mary's Hospital, Seoul

VHS medical center, Seoul

The Catholic University of Korea, St. Vincent's Hospital, Suwon

Ulsan Univeristy Hospital, Ulsan

Pusan National University Yangsan Hospital, Yangsan

All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

lead

Gi-Byoung Nam

OTHER

NCT03718559 - Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter